Co-led Antares Therapeutics' $177M Series A for precision oncology medicines.
Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need
Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need.